bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
296 hedge funds and large institutions have $9.26B invested in bluebird bio in 2017 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 96 increasing their positions, 97 reducing their positions, and 24 closing their positions.
225% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 24
51% more call options, than puts
Call options by funds: $256M | Put options by funds: $170M
34% more capital invested
Capital invested by funds: $6.9B → $9.26B (+$2.36B)
22% more funds holding
Funds holding: 243 → 296 (+53)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.3% less ownership
Funds ownership: 8.51% → 8.21% (-0.3%)
1% less repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 97
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$99.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$81.9M |
| 3 |
Two Sigma Advisers
New York
|
+$70.2M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$66.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$57.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$204M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$47.4M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$27.7M |
| 4 |
State Street
Boston,
Massachusetts
|
-$26.4M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$24.5M |
BLUE Hedge Fund Activity: Q4 2017 in Review
296 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q4 2017, worth a combined $9.26B — up 34% from $6.9B a quarter earlier.
Buyers outnumbered sellers: 78 funds opened new BLUE positions and 24 closed out — a net gain of 54 holders — while 96 added to existing stakes and 97 trimmed.
The largest buyer was Capital World Investors, adding an estimated $99.4M. The largest seller was Wellington Management Group, cutting an estimated $204M.
- 296 institutional investors held bluebird bio (BLUE) as of Q4 2017, up from 243 in Q3 2017.
- Funds reported $9.26B of bluebird bio stock for Q4 2017, up 34% quarter-over-quarter.
- 78 funds opened new bluebird bio positions in Q4 2017 and 24 closed out, a net change of +54 holders.
- The largest bluebird bio buyer in Q4 2017 was Capital World Investors, an estimated $99.4M added.
- The largest bluebird bio seller in Q4 2017 was Wellington Management Group, an estimated $204M sold.
Based on aggregated 13F filings for Q4 2017.